glp-1 risk factors GLP-1s may reduce cancer for adults with obesity Risk of pancreatic cancer associated

Always confirm medical decisions with a qualified healthcare professional

Clinical Implications of ADAs The presence of ADAs in patients receiving GLP-1 receptor agonists may lead to: 3.5

By occupying these receptors, L-theanine mildly blocks excitatory stimuli, preventing the brain from becoming overstimulated and protecting neurons from excitotoxicity without shutting down normal cognitive function

References Gwyer D, Wragg NM, Wilson SL

About the research The STEP 1 trial published in the New England Journal of Medicine was a randomized, double-blind, placebo-controlled study that followed more than 1,900 adults with overweight or obesity (but without diabetes) for 68 weeks